Merck reports results of phase 3 trial Evaluating ZERBAXA® (ceftolozane and tazobactam)
Merck announced results from ASPECT-NP, a randomized, double-blind, multi-center Phase 3 clinical trial evaluating efficacy and safety of ZERBAXA® (ceftolozane and tazobactam) for treatment of adult patients with ventilated nosocomial (hospital acquired) pneumonia. April 13, 2019